Pharmacokinetics of Mitomycin C Following Hepatic Arterial Chemoembolization with Gelfoam
1992

Pharmacokinetics of Mitomycin C After Chemoembolization

Sample size: 12 publication Evidence: moderate

Author Information

Author(s): Jin Wen Ding, Zai De Wu, Roland Andersson, Stig Bengmark

Primary Institution: Tongji Medical University, Wuhan, China; Lund University, Sweden

Hypothesis

Does gelfoam supplementation delay the clearance of mitomycin C from the liver?

Conclusion

Gelfoam does not significantly delay the clearance of mitomycin C from the liver.

Supporting Evidence

  • The pharmacokinetics of mitomycin C were similar in both treatment groups.
  • No significant differences in drug clearance were observed.
  • Gelfoam did not prolong the drug's presence in the liver.

Takeaway

The study tested if a substance called gelfoam could help keep a cancer drug in the liver longer, but it found that it doesn't really help.

Methodology

Twelve mongrel dogs were divided into two groups to compare the pharmacokinetics of mitomycin C with and without gelfoam using blood sampling and high performance liquid chromatography.

Limitations

The study was conducted on a small sample size of dogs, which may not fully represent human responses.

Participant Demographics

Twelve mongrel dogs weighing 12-16 Kg.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication